← all works
RETRACTED ARTICLE: Sensitization of MDA-MBA231 breast cancer cell to docetaxel by myricetin loaded into biocompatible lipid nanoparticles via sub-G1 cell cycle arrest mechanism
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Post-publication record
- Nature
- Retraction
- Reason
- Duplication of/in Image;Euphemisms for Duplication;Investigation by Journal/Publisher;Objections by Author(s);Original Data and/or Images not Provided and/or not Available;Unreliable Data;
- Date
- 12/10/2024 0:00
- Flagged by OpenAlex?
- Yes
Source: Retraction Watch, joined by DOI. OpenAlex records retraction as is_retracted, a boolean over a state space with at least four values, so it cannot express an expression of concern, a correction or a reinstatement — it reports them as false, which reads as “fine”.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- Naunyn-Schmiedeberg s Archives of Pharmacology
- Topic
- Nanoparticle-Based Drug Delivery
- Field
- Materials Science
- Canadian institutions
- University of Alberta
- Funders
- —
- Keywords
- MyricetinDocetaxelSurvivinApoptosisViability assayChemistryCytotoxicityCancer cellMTT assayCancer researchPharmacologyCancerMedicineBiochemistryIn vitroQuercetinInternal medicineAntioxidant
- Has abstract in OpenAlex
- no